For many, the long-term effects of gadolinium contrast agents are a mystery. This patient-led survey, featuring the experiences of over 300 individuals, including 185 with laboratory-confirmed gadolinium retention, offers a unique window into the real-world challenges and patterns emerging after contrast-enhanced MRIs. While this report cannot prove causation, it highlights critical associations and signals that deserve further attention.
If you are a medical professional watching this, you are likely sceptical. You should be. You rely on GBCAs to diagnose cancer and MS. We aren't asking you to stop diagnosing. We are asking you to look at a new toxicological pattern that matches the FDA's 2015 admission of retention.